Sains Malaysiana 50(12)(2021): 3647-3657

http://doi.org/10.17576/jsm-2021-5012-15

Fluoxetine Affects Intestinal Motility via 5-HT₃ and Muscarinic Receptors in ex vivo Mouse Model

(Kesan Fluoxetin terhadap Motiliti Usus melalui Reseptor 5-HT₃ dan Bermuskarina pada Model Tikus ex vivo)

PISSARED KHUITUAN^1,2*, CHOTIKA NHAEMCHEI^2,3, SAKDA PRADAB^2,4, SAKENA K-DA^1,2 & NIPAPORN KONTHAPAKDEE¹

¹Division of Health and Applied Sciences, Faculty of Science, Prince of Songkla University, Hat Yai, Songkhla, 90110 Thailand

²Gut Biology and Microbiota Research Unit, Prince of Songkla University, Hat Yai, Songkhla, 90110 Thailand

³Division of Physical Science, Faculty of Science, Prince of Songkla University, Hat Yai, Songkhla, 90110 Thailand

⁴Faculty of Traditional Thai Medicine, Prince of Songkla University, Songkhla, 90110 Thailand

Diserahkan: 6 Januari 2021/Diterima: 22 Mac 2021

ABSTRACT

Fluoxetine, a selective serotonin reuptake inhibitor anti-depressant, causes undesirable side effects, including diarrhea and constipation. This research investigated the direct effects of fluoxetine at 0.001, 0.01, 0.1, 1, 10, and 100 µM on duodenal and proximal colonic tissue contractions. The investigation aimed to determine related mechanisms using an isolated mouse intestine model. Our study showed that fluoxetine at 0.001 μM increased the amplitude of contraction in colonic tissue but decreased the amplitude in duodenal tissue. The direct application of higher concentrations of fluoxetine (1, 10, and 100 µM) reduced the amplitude of contractions in proximal colonic tissue. Moreover, we found that the stimulatory effect of 0.001 µM fluoxetine on the tone of contractions could be prevented by pre-incubating the tissue in ondansetron and atropine. Our findings suggest that the inhibition of the effect of fluoxetine was mainly mediated via 5-HT₃ receptors and muscarinic signaling. These findings might explain the conflicting gastrointestinal symptoms caused by fluoxetine.

Keywords: Intestinal contraction; selective serotonin reuptake inhibitor; 5-hydroxytryptamine

ABSTRAK

Fluoxetin ialah perencat pengambilan anti-depresan serotonin yang memilih, menyebabkan kesan sampingan yang tidak diingini, termasuk cirit-birit dan sembelit. Penyelidikan ini mengkaji kesan langsung fluoxetin pada 0.001, 0.01, 0.1, 1, 10 dan 100 µM pada pengecutan tisu kolon duodenum dan proksimal. Penyelidikan bertujuan untuk menentukan mekanisme yang berkaitan dengan menggunakan model usus tikus yang terpencil. Kajian menunjukkan bahawa fluoxetin pada 0.001 μM meningkatkan amplitud penguncupan pada tisu kolon tetapi menurunkan amplitud pada tisu duodenum. Aplikasi langsung kepekatan fluoxetin yang lebih tinggi (1, 10 dan 100 µM) mengurangkan amplitud pengecutanpada tisu kolon proksimal. Selain itu, didapati bahawa kesan perangsang 0.001 µM fluoxetin pada nadapengecutan dapat dicegah dengan pra-inkubasi tisu dalam ondansetron dan atropin. Penemuan kami menunjukkan bahawa penghambatan kesan fluoxetin terutamanya dimediasi melalui reseptor 5-HT3 dan isyarat bermuskarina. Penemuan ini dapat menjelaskan gejala gastrointestinal yang bertentangan yang disebabkan oleh fluoxetin.

Kata kunci: Pengecutan usus; perencat pengambilan serotonin selektif; 5-hidroksitriptamina

RUJUKAN

Afzal, A., Sharif, M., Khan, A., Khan, B.T. & Ara, I. 2018. Fluoxetine causes decrease in intestinal motility. International Journal of Basic & Clinical Pharmacology 7(3): 429-432.

Bastos, A.G., Guimarães, L.S.P. & Trentini, C.M. 2013. Neurocognitive changes in depressed patients in psychodynamic psychotherapy, therapy with fluoxetine and combination therapy. Journal of Affective Disorders 151(3): 1066-1075.

Burnstock, G. 1958. The effect of drugs on spontaneous motility and on response to stimulation of the extrinsic nerves of the gut of a teleostean fish. British Journal of Pharmacology and Chemotherapy 13(3): 216-226.

Colle, R., Masson, P., Verstuyft, C., Fève, B., Werner, E., Boursier‐Neyret, C., Walther, B., David, D.J., Boniface, B., Falissard, B., Chanson, P., Corruble, E. & Becquemont, L. 2020. Peripheral tryptophan, serotonin, kynurenine, and their metabolites in major depression: A case-control study. Psychiatry and Clinical Neurosciences 74(2): 112-117.

Costescu, M., Paunescu, H., Coman, O.A., Coman, L. & Fulga, I. 2019. Antidepressant effect of the interaction of fluoxetine with granisetron. Experimental and Therapeutic Medicine 18(6): 5108-5111.

De Ponti, F. 2004. Pharmacology of serotonin: What a clinician should know. Gut 53(10): 1520-1535.

Fan, P. & Weight, F.F. 1994. The effect of atropine on the activation of 5-hydroxytryptamine3 channels in rat nodose ganglion neurons. Neuroscience 62(4): 1287-1292.

Gelenberg, A.J., Freeman, M.P., Markowitz, J.C., Rosenbaum, J.F., Thase, M.E., Trivedi, M.H. & Van Rhoads, R.S. 2010. Practice Guideline for the Treatment of Patients with Major Depressive Disorder. 3rd ed. American Psychiatric Association.

Gershon, M.D. & Tack, J. 2007. The serotonin signaling system: From basic understanding to drug development for functional GI disorders. Gastroenterology 132(1): 397-414.

Gutierrez-Galve, L., Stein, A., Hanington, L., Heron, J., Lewis, G., O’Farrelly, C. & Ramchandani, P.G. 2019. Association of maternal and paternal depression in the          postnatal period with offspring depression at age 18 years. JAMA Psychiatry 76(3): 290-296.

Gwynne, R.M., Clarke, A.J., Furness, J.B. & Bornstein, J.C. 2014. Both exogenous 5-HT and endogenous 5-HT, released by fluoxetine, enhance distension evoked propulsion in guinea-pig ileum in vitro. Frontiers in Neuroscience 8: 301.

James, S.L., Abate, D., Abate, K.H., Abay, S.M., Abbafati, C., Abbasi, N., Abbastabar, H., Abd-Allah, F., Abdela, J., Abdelalim, A., Abdollahpour, I., Abdulkader, R.S., Abebe, Z., Abera, S.F., Abil, O.Z., Abraha, H.N., Abu-Raddad, L.J., Abu-Rmeileh, N.M.E., Accrombessi, M.M.K., … & Murray, C.J.L. 2018. Global, regional, and national incidence, prevalence, and years lived with disability for 354 diseases and injuries for 195 countries and territories, 1990-2017: A systematic analysis for the global burden of disease study 2017. The Lancet 392(10159): 1789-1858.

Kannen, V., Marini, T., Turatti, A., Carvalho, M.C., Brandão, M.L., Jabor, V.A.P., Bonato, P.S., Ferreira, F.R., Zanette, D.L., Silva, W.A. & Garcia, S.B. 2011. Fluoxetine induces preventive and complex effects against colon cancer development in epithelial and stromal areas in rats. Toxicology Letters 204(2-3): 134-140.

K-da, S., Peerakietkhajorn, S., Siringoringo, B., Muangnil, P., Wichienchot, S. & Khuituan, P. 2020. Oligosaccharides from Gracilaria fisheri ameliorate gastrointestinal dysmotility and gut dysbiosis in colitis mice. Journal of Functional Foods 71: 104021.

Kashani, L., Eslatmanesh, S., Saedi, N., Niroomand, N., Ebrahimi, M., Hosseinian, M., Foroughifar, T., Salimi, S. & Akhondzadeh, S. 2017. Comparison of saffron versus fluoxetine in treatment of mild to moderate postpartum depression: A double-blind, randomized clinical trial. Pharmacopsychiatry 50(2): 64-68.

Lochner, M. & Thompson, A.J. 2016. The muscarinic antagonists scopolamine and atropine are competitive antagonists at 5-HT3 receptors. Neuropharmacology 108: 220-228.

Mawe, G.M. & Hoffman, J.M. 2013. Serotonin signaling in the gastrointestinal tract: Nature reviews. Nature Reviews Gastroenterology & Hepatology 10(8): 473-486.

Sohel, A.J., Shutter, M.C. & Molla, M. 2020. Fluoxetine. In StatPearls. Treasure Island (FL): StatPearls Publishing.

*Pengarang untuk surat-menyurat; email: pissared.k@psu.ac.th